瑞司美替羅

化合物

瑞司美替羅(Resmetirom)是一種用於治療非酒精性脂肪性肝炎(NASH) 的實驗性藥物。[1][2]它是甲狀腺激素受體-β的選擇性激動劑,可增加肝臟脂肪代謝並降低身體中過量脂肪的毒性。 [1]

瑞司美替羅
法律規範狀態
法律規範
  • Investigational
識別資訊
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
化學資訊
化學式C17H12Cl2N6O4
摩爾質量435.22 g·mol−1
3D模型(JSmol英語JSmol
  • CC(C)C1=CC(=NNC1=O)OC2=C(C=C(C=C2Cl)N3C(=O)NC(=O)C(=N3)C#N)Cl

截至2023年,處於III期臨床試驗階段。 [3] [4]

參考文獻

編輯
  1. ^ 1.0 1.1 Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. November 2019, 394 (10213): 2012–2024. PMID 31727409. S2CID 207976212. doi:10.1016/S0140-6736(19)32517-6. 
  2. ^ Non-Alcoholic Fatty Liver Disease (NAFLD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape. Yahoo! Finance. January 23, 2023 [2023-05-15]. (原始內容存檔於2023-02-07). 
  3. ^ Harrison SA. A 52-Week Phase 3 Clinical Trial of Resmetirom in 180 Patients with Well-Compensated NASH Cirrhosis. AASLD: The Liver Meeting. [2023-05-15]. (原始內容存檔於2023-05-27). 
  4. ^ Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis (新聞稿). Madrigal Pharmaceuticals. December 19, 2022 [2023-05-15]. (原始內容存檔於2023-12-16).